The invention relates to a pharmaceutical combination which comprises (a) a phosphoinositide 3-kinase inhibitor compound of formula (I) and (b) a mTOR inhibitor for the treatment of a target of rapamycin (mTOR) kinase dependent disease, especially a cancer disease； a pharmaceutical composition comprising such a combination； the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease； a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use； and to a method of treatment of a warm-blooded animal, especially a human.
